Scientists have fashioned a cancer-fighting molecule from two improbable sources: an antibody fragment borrowed from sharks and a shortened toxin drawn from a common bacterium. Aimed at ERα36, a receptor that sits on the outer surface of breast cancer cells and helps drive some of the most stubborn forms of the disease, it destroyed those cells in laboratory dishes and shrank tumors in mice. The work is a promising step in a long human effort to reach targets that ordinary drugs cannot, though whether it will ever help a patient remains an open question for the years ahead.
Shark-Derived Antibody Immunotoxin Silences Membrane Receptor ERα36 and Rewires Breast Cancer Metabolism in Preclinical Models
A shark antibody fused to a bacterial toxin, aimed at a receptor few could reach
Scientists have fashioned a cancer-fighting molecule from two improbable sources: an antibody fragment borrowed from sharks and a shortened toxin drawn from a common bacterium. Aimed at ERα36, a receptor that sits on the outer surface of breast cancer cells and helps drive some of the most stubborn forms of the disease, it destroyed those cells in laboratory dishes and shrank tumors in mice. The work is a promising step in a long human effort to reach targets that ordinary drugs cannot, though whether it will ever help a patient remains an open question for the years ahead.
Researchers have built a cancer-killing molecule from two unlikely parts. One is a small antibody fragment derived from sharks, prized for its ability to reach hidden surfaces of proteins. The other is a shortened toxin from the bacterium Pseudomonas aeruginosa. Together they form a compound aimed at ERα36, a variant of the estrogen receptor that sits on the cell surface rather than inside the nucleus. This receptor drives rapid signaling in cancer cells and is often overexpressed in aggressive, therapy-resistant tumors, yet it has been hard to exploit because few molecules bind it tightly and selectively.
The team searched a library of shark antibodies and isolated two strong binders, then engineered one of them, TH4, into an immunotoxin called TH4-PE24. Its grip on ERα36 is exceptionally tight, and it selectively kills cancer cells that carry the receptor. It works on two fronts: it degrades the receptor itself and shuts down the PI3K/AKT and MAPK/ERK pathways that cancer cells use to survive and grow.
In mice with breast tumors, the molecule produced significant shrinkage, and the authors observed no systemic toxicity. The researchers also used it as a probe, finding that it reshapes cancer cell metabolism in several ways, a direction they describe as full of unknowns.
The authors see the approach as a platform that could be adapted to other membrane receptors beyond the reach of conventional antibodies. For now, though, every result comes from cell lines and animals. Whether the molecule is safe and effective in people is the question the next stage must answer.
Researchers have built a cancer-killing molecule out of two unlikely parts: a single-domain antibody derived from sharks and a trimmed-down toxin from the bacterium Pseudomonas aeruginosa. Aimed at a hard-to-reach receptor on breast cancer cells, the combination killed those cells in the lab and shrank tumors in mice, according to a paper in Nature's family of journals.
The target is ERα36, a splice variant of estrogen receptor α that sits on the cell membrane rather than inside the nucleus. It mediates rapid, non-genomic estrogen signaling, and it is frequently overexpressed in aggressive and therapy-resistant breast cancers. Despite that profile, it has been difficult to exploit clinically. What has been missing is a ligand with both high affinity and high specificity for its extracellular domain.
The team went to sharks for one. They constructed a phage display immune library of shark variable new antigen receptors, known as VNARs, which are small single-domain antibodies. From that library they isolated two high-affinity VNARs, called FR6 and TH4, each recognizing a different epitope on ERα36.
They then engineered TH4 further, fusing it to PE24, a truncated form of Pseudomonas aeruginosa exotoxin. The result is a recombinant immunotoxin named TH4-PE24. It binds ERα36 with a dissociation constant (KD) of 0.751 nanomoles per liter, and it kills ERα36-positive breast cancer cells selectively, with an IC50 of 1.54 nanomoles per liter.
The mechanism appears to be twofold. TH4-PE24 drives degradation of ERα36 itself and suppresses two signaling pathways that cancer cells lean on for growth and survival, PI3K/AKT and MAPK/ERK. In xenograft models, the immunotoxin produced significant antitumor effects, and the authors report no observable systemic toxicity.
The researchers also used the molecule as a probe. How ERα36 shapes tumor metabolism is, in their words, a new research direction with many unknowns. Treating cells with TH4-PE24 triggered broad metabolic reprogramming, including disruption of nucleotide metabolism, ABC transporters and central carbon metabolism.
The authors frame the work as a platform as much as a single drug. Because the design is modular, the same approach could be applied to other membrane receptors that conventional antibodies cannot reach, including additional immune checkpoint molecules.
The evidence so far is preclinical, drawn from cell lines and mouse xenografts. Whether TH4-PE24 is safe and effective in people has not been tested, and that is the question any next stage would have to answer.
Bemerkenswerte Zitate
ERα36-mediated metabolic regulation in breast cancer is a new research direction with many aspects unknown.— Study authors
Möchten Sie die ganze Geschichte?
Das Original lesen bei Nature ↗
Health & Medicine